| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2158666 | Radiotherapy and Oncology | 2011 | 6 Pages |
BackgroundDespite significant improvements in the treatment of head and neck cancer (HNC), lymph node recurrences remain a clinical challenge after primary radiotherapy. The value of interstitial (IRT) brachytherapy (BRT) for control of lymph node recurrence remains unclear. In order to clarify its role a retrospective review was undertaken on the value of computed tomography (CT)-guided IRT high-dose-rate (HDR)-BRT in isolated recurrent disease from HNC.Patients and methodsFrom 2000 to 2007, 74 patients were treated for inoperable recurrent cervical lymphadenopathy. All patients had previously been treated with radical radiotherapy or chemoradiation with or without surgery. The HDR-BRT delivered a median salvage dose of 30.0 Gy (range, 12.0–36.0 Gy) in twice-daily fractions of 2.0–5.0 Gy in 71 patients and of 30.0 Gy (range, 10.0–36.0 Gy) in once-daily fractions of 6.0–10.0 Gy in three patients.ResultsThe overall and disease-free survival rates at one, two and three years were 42%, 19%, 6%, and 42%, 37% and 19%, respectively. The local control probability at one, two and three years was 67% at all three time points. Grade III–IV complications occurred in 13% of patients.ConclusionsIn patients with inoperable recurrent neck disease from HNC, hypofractionated accelerated CT-guided IRT-HDR-BRT can play an important role in providing palliation and tumor control.
